UBS raised the firm’s price target on BrightSpring Health (BTSG) to $55 from $53 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health price target raised to $60 from $49 at TD Cowen
- BrightSpring Health price target raised to $55 from $53 at UBS
- BrightSpring Health price target raised to $52 from $50 at Mizuho
- BrightSpring: Specialty Pharmacy Growth, Structural Tailwinds, and Upside to Long-Term EBITDA Targets Support Buy Rating
- BrightSpring: Diversified Growth and Attractive Valuation Underpin Buy Rating